4 documents found, page 1 of 1
The interference of COVID-19 in the male reproductive system: Important questio...
Carvalho, Renata Cristina de; Groner, Matheus Ferreira; Camillo, Jacqueline; Ferreira, Paulo Roberto Abrão; Fraietta, Renato
HEPATITIS C IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM: BURDEN OF DISEASE
Castelo, Adauto; Mello, Carlos Eduardo BrandÃo; Teixeira, Rosangela; Madruga, Jose Valdez Ramalho; Reuter, Tania; Pereira, Leila Maria Moreira BeltrãoMade available in DSpace on 2019-10-03T17:31:13Z (GMT). No. of bitstreams: 0 Previous issue date: 2018-12-01. Added 1 bitstream(s) on 2019-10-04T16:20:23Z : No. of bitstreams: 1 S0004-28032018002400329.pdf: 264375 bytes, checksum: a057596e119e73acaf2321d69db282bd (MD5); RESUMOCONTEXTO:A infecção pelo vírus da hepatite C (HCV) é uma das principais causas de hepatite C crônica e provoca implicações graves para pa...
Peginterferon still has a place in the treatment of hepatitis C caused by genot...
Grando, Aline Vitali; Ferreira, Paulo Roberto Abrão; Pessôa, Mário Guimarães; Mazo, Daniel Ferraz de Campos; Brandão-Mello, Carlos EduardoDespite recent advances in therapy for chronic hepatitis C (CHC), the disease caused by genotype 3 virus (GEN3) is still considered a treatment challenge in certain patient subgroups. The aim of this retrospective study was to evaluate the effectiveness and safety of the peginterferon (Peg-IFN) and ribavirin (RBV) combination treatment for GEN3/CHC patients, and to evaluate sustained virological response (SVR) ...
Effectiveness and safety of first-generation protease inhibitors in real-world ...
Callefi, Luciana Azevedo; Villela-Nogueira, Cristiane Alves; de Barros Tenore, Simone; Carnaúba-Júnior, Dimas; Coelho, Henrique Sérgio MoraesOBJECTIVE: To evaluate the effectiveness and safety of first-generation protease inhibitors for the treatment of genotype 1 hepatitis C virus-infected patients at Brazilian reference centers. METHODS: This multicenter cross-sectional study included hepatitis C virus genotype 1 monoinfected patients treated with Peg-interferon, ribavirin, and either boceprevir (n=158) or telaprevir (n=557) between July 2013 and ...